Search Results - "Wilner, Keith"

Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer by Solomon, Benjamin J, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Tang, Yiyun, Wilner, Keith D, Blackhall, Fiona, Mok, Tony S

“…Purpose The phase III PROFILE 1014 trial compared crizotinib with chemotherapy as first-line treatment in patients with anaplastic lymphoma kinase (ALK)…”
Get full text

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer by Solomon, Benjamin J, Mok, Tony, Kim, Dong-Wan, Wu, Yi-Long, Nakagawa, Kazuhiko, Mekhail, Tarek, Felip, Enriqueta, Cappuzzo, Federico, Paolini, Jolanda, Usari, Tiziana, Iyer, Shrividya, Reisman, Arlene, Wilner, Keith D, Tursi, Jennifer, Blackhall, Fiona

“…The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater…”
Get full text

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration by Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.

“…MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs) 1 . These alterations are associated with increased MET activity and…”
Get full text

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib by Costa, Daniel B, Kobayashi, Susumu, Pandya, Shuchi S, Yeo, Wee-Lee, Shen, Zhongzhou, Tan, Weiwei, Wilner, Keith D

Get full text

Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer by Wu, Yi-Long, Yang, James Chih-Hsin, Kim, Dong-Wan, Lu, Shun, Zhou, Jianying, Seto, Takashi, Yang, Jin-Ji, Yamamoto, Noboru, Ahn, Myung-Ju, Takahashi, Toshiaki, Yamanaka, Takeharu, Kemner, Allison, Roychowdhury, Debasish, Paolini, Jolanda, Usari, Tiziana, Wilner, Keith D, Goto, Koichi

“…Purpose Approximately 1% to 2% of non-small-cell lung cancers (NSCLCs) harbor a c-ros oncogene 1 ( ROS1) rearrangement. Crizotinib, an inhibitor of anaplastic…”
Get full text

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers by BERGETHON, Kristin, SHAW, Alice T, MARK, Eugene J, BATTEN, Julie M, HAIQUAN CHEN, WILNER, Keith D, KWAK, Eunice L, CLARK, Jeffrey W, CARBONE, David P, HONGBIN JI, ENGELMAN, Jeffrey A, MINO-KENUDSON, Mari, IGNATIUS OU, Sai-Hong, PAO, William, IAFRATE, A. John, KATAYAMA, Ryohei, LOVLY, Christine M, MCDONALD, Nerina T, MASSION, Pierre P, SIWAK-TAPP, Christina, GONZALEZ, Adriana, RONG FANG

“…Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs)…”
Get full text

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases by Costa, Daniel B, Shaw, Alice T, Ou, Sai-Hong I, Solomon, Benjamin J, Riely, Gregory J, Ahn, Myung-Ju, Zhou, Caicun, Shreeve, S Martin, Selaru, Paulina, Polli, Anna, Schnell, Patrick, Wilner, Keith D, Wiltshire, Robin, Camidge, D Ross, Crinò, Lucio

“…Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC). The clinical benefits of crizotinib in…”
Get full text

Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014 by Solomon, Benjamin J, Cappuzzo, Federico, Felip, Enriqueta, Blackhall, Fiona H, Costa, Daniel B, Kim, Dong-Wan, Nakagawa, Kazuhiko, Wu, Yi-Long, Mekhail, Tarek, Paolini, Jolanda, Tursi, Jennifer, Usari, Tiziana, Wilner, Keith D, Selaru, Paulina, Mok, Tony S K

“…Intracranial efficacy of first-line crizotinib versus chemotherapy was compared prospectively in the phase III PROFILE 1014 study in ALK-positive…”
Get full text

MET Amplification Identifies a Small and Aggressive Subgroup of Esophagogastric Adenocarcinoma With Evidence of Responsiveness to Crizotinib by LENNERZ, Jochen K, KWAK, Eunice L, SALGIA, Ravi, BANG, Yung-Jue, CLARK, Jeffrey W, SOLOMON, Benjamin J, JOHN IAFRATE, A, ACKERMAN, Allison, MICHAEL, Michael, FOX, Stephen B, BERGETHON, Kristin, LAUWERS, Gregory Y, CHRISTENSEN, James G, WILNER, Keith D, HABER, Daniel A

“…Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a molecular marker for targeted therapy. We examined a GEC cohort with…”
Get full text

Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer by Shaw, Alice T, Kim, Dong-Wan, Nakagawa, Kazuhiko, Seto, Takashi, Crinó, Lucio, Ahn, Myung-Ju, De Pas, Tommaso, Besse, Benjamin, Solomon, Benjamin J, Blackhall, Fiona, Wu, Yi-Long, Thomas, Michael, O'Byrne, Kenneth J, Moro-Sibilot, Denis, Camidge, D. Ross, Mok, Tony, Hirsh, Vera, Riely, Gregory J, Iyer, Shrividya, Tassell, Vanessa, Polli, Anna, Wilner, Keith D, Jänne, Pasi A

“…In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based…”
Get full text

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations by Mok, Tony S., Cheng, Ying, Zhou, Xiangdong, Lee, Ki Hyeong, Nakagawa, Kazuhiko, Niho, Seiji, Chawla, Alka, Rosell, Rafael, Corral, Jesus, Migliorino, Maria Rita, Pluzanski, Adam, Noonan, Kay, Tang, Yiyun, Pastel, Malaika, Wilner, Keith D., Wu, Yi-Long

“…Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of dacomitinib versus gefitinib in newly diagnosed patients with advanced…”
Get full text

Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer by Wu, Yi-Long, Lu, Shun, Lu, You, Zhou, Jianying, Shi, Yuan-Kai, Sriuranpong, Virote, Ho, James C M, Ong, Choo Khoon, Tsai, Chun-Ming, Chung, Chin-Hee, Wilner, Keith D, Tang, Yiyun, Masters, Elizabeth T, Selaru, Paulina, Mok, Tony S

“…The phase III randomized PROFILE 1014 study demonstrated superiority of crizotinib to first-line chemotherapy in prolonging progression-free survival (PFS) in…”
Get more information

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer by Shaw, Alice T, Ou, Sai-Hong I, Bang, Yung-Jue, Camidge, D. Ross, Solomon, Benjamin J, Salgia, Ravi, Riely, Gregory J, Varella-Garcia, Marileila, Shapiro, Geoffrey I, Costa, Daniel B, Doebele, Robert C, Le, Long Phi, Zheng, Zongli, Tan, Weiwei, Stephenson, Patricia, Shreeve, S. Martin, Tye, Lesley M, Christensen, James G, Wilner, Keith D, Clark, Jeffrey W, Iafrate, A. John

“…About 1% of non–small-cell lung cancers have ROS1 rearrangements. This oncogene is inhibited by crizotinib. In a cohort of 50 patients with ROS1 -rearranged…”
Get full text

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer by FLAHERTY, Keith T, LORUSSO, Patricia M, DEMICHELE, Angela, ABRAMSON, Vandana G, COURTNEY, Rachel, RANDOLPH, Sophia S, SHAIK, M. Naveed, WILNER, Keith D, O'DWYER, Peter J, SCHWARTZ, Gary K

“…To identify the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of the first-in-class, oral CDK4/6 inhibitor PD 0332991 administered once daily…”
Get full text

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study by Mossé, Yael P, Dr, Lim, Megan S, MD, Voss, Stephan D, MD, Wilner, Keith, PhD, Ruffner, Katherine, MD, Laliberte, Julie, Rolland, Delphine, Balis, Frank M, Prof, Maris, John M, Prof, Weigel, Brenda J, MD, Ingle, Ashish M, MS, Ahern, Charlotte, PhD, Adamson, Peter C, Prof, Blaney, Susan M, Prof

“…Summary Background Various human cancers have ALK gene translocations, amplifications, or oncogenic mutations, such as anaplastic large-cell lymphoma,…”
Get full text

Activity and safety of crizotinib in patients with ALK -positive non-small-cell lung cancer: updated results from a phase 1 study by Camidge, D Ross, Dr, Bang, Yung-Jue, Prof, Kwak, Eunice L, MD, Iafrate, A John, MD, Varella-Garcia, Marileila, Prof, Fox, Stephen B, Prof, Riely, Gregory J, MD, Solomon, Benjamin, MBBS, Ou, Sai-Hong I, MD, Kim, Dong-Wan, Prof, Salgia, Ravi, Prof, Fidias, Panagiotis, MD, Engelman, Jeffrey A, MD, Gandhi, Leena, MD, Jänne, Pasi A, MD, Costa, Daniel B, MD, Shapiro, Geoffrey I, MD, LoRusso, Patricia, DO, Ruffner, Katherine, MD, Stephenson, Patricia, ScD, Tang, Yiyun, PhD, Wilner, Keith, PhD, Clark, Jeffrey W, MD, Shaw, Alice T, MD

“…Summary Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs). We assessed the tolerability and activity of crizotinib in…”
Get full text

Crizotinib in ALK-Rearranged Inflammatory Myofibroblastic Tumor by Butrynski, James E, D'Adamo, David R, Hornick, Jason L, Dal Cin, Paola, Antonescu, Cristina R, Jhanwar, Suresh C, Ladanyi, Marc, Capelletti, Marzia, Rodig, Scott J, Ramaiya, Nikhil, Kwak, Eunice L, Clark, Jeffrey W, Wilner, Keith D, Christensen, James G, Jänne, Pasi A, Maki, Robert G, Demetri, George D, Shapiro, Geoffrey I

“…A subgroup of inflammatory myoblastic tumors (IMTs) have gene rearrangements that activate anaplastic lymphoma kinase (ALK). The authors report a case of IMT…”
Get full text

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Performance Status Work Group by Magnuson, Allison, Bruinooge, Suanna S, Singh, Harpreet, Wilner, Keith D, Jalal, Shadia, Lichtman, Stuart M, Kluetz, Paul G, Lyman, Gary H, Klepin, Heidi D, Fleury, Mark E, Hirsch, Brad, Melemed, Allen, Arnaldez, Fernanda I, Basu Roy, Upal, Schenkel, Caroline, Sherwood, Shimere, Garrett-Mayer, Elizabeth

“…Performance status (PS) is one of the most common eligibility criteria. Many trials are limited to patients with high-functioning PS, resulting in important…”
Get full text

Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1 by Awad, Mark M, Katayama, Ryohei, McTigue, Michele, Liu, Wei, Deng, Ya-Li, Brooun, Alexei, Friboulet, Luc, Huang, Donghui, Falk, Matthew D, Timofeevski, Sergei, Wilner, Keith D, Lockerman, Elizabeth L, Khan, Tahsin M, Mahmood, Sidra, Gainor, Justin F, Digumarthy, Subba R, Stone, James R, Mino-Kenudson, Mari, Christensen, James G, Iafrate, A. John, Engelman, Jeffrey A, Shaw, Alice T

“…Crizotinib inhibits various kinases, including ALK and ROS1. In a patient with lung cancer and an activating ROS1 rearrangement, resistance to crizotinib…”
Get full text

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors by SASAKI, Takaaki, KOIVUNEN, Jussi, CAPELLETTI, Marzia, SHIMAMURA, Takeshi, ERCAN, Dalia, STUMPFOVA, Magda, YUN XIAO, WEREMOWICZ, Stanislawa, BUTANEY, Mohit, HEON, Stephanie, WILNER, Keith, CHRISTENSEN, James G, OGINO, Atsuko, ECK, Michel J, WONG, Kwok-Kin, LINDEMAN, Neal, GRAY, Nathanael S, RODIG, Scott J, JÄNNE, Pasi A, YANAGITA, Masahiko, NIKIFOROW, Sarah, ZHENG, Wei, LATHAN, Christopher, PAUL MARCOUX, J, JINYAN DU, OKUDA, Katsuhiro

“…Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and in cancer patients…”
Get full text